F Kullmann

Summary

Publications

  1. ncbi A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
  2. ncbi Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    Br J Cancer 100:1032-6. 2009
  3. ncbi KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy
    F Kullmann
    University of Regensburg, Regensburg, Germany
    Oncology 81:3-8. 2011
  4. ncbi Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Eur J Gastroenterol Hepatol 13:513-22. 2001
  5. ncbi Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study
    E Endlicher
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    Oncology 72:279-84. 2007
  6. ncbi Activation of the IL-4 STAT pathway in rheumatoid synovium
    U Muller-Ladner
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    J Immunol 164:3894-901. 2000
  7. ncbi Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Int J Colorectal Dis 16:238-46. 2001
  8. ncbi Bleeding jejunal diverticulosis in a patient with myasthenia gravis
    I Zuber-Jerger
    Department of Internal Medicine I, School of Medicine, University of Regensburg, 93042 Regensburg, Germany
    Diagn Ther Endosc 2008:156496. 2008

Collaborators

Detail Information

Publications8

  1. ncbi A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  2. ncbi Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    Br J Cancer 100:1032-6. 2009
    ..The addition of cetuximab to the combination of gemcitabine and oxaliplatin is well tolerated but does not increase response or survival in patients with metastatic pancreatic cancer...
  3. ncbi KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy
    F Kullmann
    University of Regensburg, Regensburg, Germany
    Oncology 81:3-8. 2011
    ..The aim of this study was to evaluate the relationship between KRAS mutations and response or survival in patients with metastatic pancreatic cancer treated with cetuximab plus chemotherapy...
  4. ncbi Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Eur J Gastroenterol Hepatol 13:513-22. 2001
    ..Further studies are required to determine the clinical implications of these abnormal findings in the absence of overt clinical symptoms...
  5. ncbi Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study
    E Endlicher
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    Oncology 72:279-84. 2007
    ..Secondary efficacy end points included response rate, time to progression (TTP), overall survival (OS) and toxicity...
  6. ncbi Activation of the IL-4 STAT pathway in rheumatoid synovium
    U Muller-Ladner
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    J Immunol 164:3894-901. 2000
    ....
  7. ncbi Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats
    F Kullmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Int J Colorectal Dis 16:238-46. 2001
    ..Further long-term studies with the present DSS colitis model in rats might also prove it as a reliable model to study the sequence high-grade dysplasia and colitis associated-cancer...
  8. ncbi Bleeding jejunal diverticulosis in a patient with myasthenia gravis
    I Zuber-Jerger
    Department of Internal Medicine I, School of Medicine, University of Regensburg, 93042 Regensburg, Germany
    Diagn Ther Endosc 2008:156496. 2008
    ..Large diverticula with fecoliths were found in both loops. Bleeding had ceased. The patient was discharged to neurology for optimizing therapy for myasthenia gravis...